Paul McGovern

HydroCision, Inc. develops, manufactures and markets fluid-jet based surgical tools. Its products include spinejet system, spinejet XL, hydrodiscectomy system and allograft system. The company was founded by Kevin P. Staid and Timothy E. Moutafis in 1994 and is headquartered in North Billerica, MA.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA.

The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA.

MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom.

Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ.

BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL.

Part of Eli Lilly & Co., Lilly Deutschland GmbH is a pharmaceutical company based in Bad Homburg, Germany. The German company manufactures pharmaceutical products. The company was founded in 1960 by Eli Lilly. The CEO is Kadir Tepebasi.

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

Danish BioVenture General Partner ApS operates as a general partner and renders investment advice to K/S Danish BioVenture. It manages the administration and acts as a representative of Danish BioVenture in external commercial relations. The company was founded on June 26, 2009 and is headquartered in Copenhagen, Denmark.

EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom.

KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA.

NavBio AG provides business and management consulting services.

Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA.

Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY.

Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts.

Xenimmune Therapeutics, Inc. develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection. The private company is located in the US.

JPMorgan Investment Bank operates as an investment banking firm. The company is headquartered in Houston, TX.